GlassScriptPhysician profile
Shahab Zaidi
NPI 1346457660
$2,976.81
in general payments reported to CMS, 2019-2025
29 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $451 · 2021: $471 · 2022: $362 · 2023: $385 · 2024: $393 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719 · Honoraria: $300 · Long Term Medical Supply Or Device Loan: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.22 |
| Honoraria | $300.00 |
| Long Term Medical Supply Or Device Loan | $229.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $429.75 | 2019-2022 | |
| Abbott Laboratories | $417.50 | 2021-2024 | Freestyle Libre 3, Precision Xtra, Freestyle Copilot |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Lilly USA, LLC | $193.16 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $167.07 | 2019-2023 | Evenity, Prolia |
| Medtronic, INC. | $135.77 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $127.69 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2021 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Dexcom, INC. | $99.70 | 2021-2023 | Dexcom G6 Transmitter |
| Companion Medical, INC. | $98.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.64 | 2020-2022 | |
| Radius Health, INC. | $73.69 | 2019-2024 | Tymlos |
| Corcept Therapeutics | $66.07 | 2020-2025 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.34 | 2019-2023 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $63.65 | 2021-2023 | Tepezza |
| Shire North American Group INC | $58.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $40.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.33 | 2023 | |
| Alexion Pharmaceuticals, INC. | $30.31 | 2023 | Strensiq |
| Kyowa Kirin, INC. | $26.77 | 2023 | Crysvita |
| Pfizer INC. | $20.26 | 2023 | |
| Accord Healthcare, INC. | $18.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.69 | 2023 | Evkeeza |
| Recordati_rare_diseases_inc. | $17.51 | 2023 | Isturisa |
| Amarin Pharma, INC. | $14.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2019 | |
| Ibsa Pharma INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahab Zaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.